tumor sequencing

NantHealth's net loss fell by 37 percent, to $14.7 million, as revenue from software-related revenue jumped by 23 percent while expenses fell.

The embattled company saw its net loss narrow during the first quarter, in part due to a new policy of giving away fewer nonreimbursed GPS Cancer and Liquid GPS molecular test orders than in the past.

The company's net loss more than doubled in Q4 to $49.1 million.

The issue, discovered in late October, affected TMB reporting for up to 800 FoundationOne CDx tests during a short period of time and was quickly resolved.

While orders of its Liquid GPS are increasing, Soon-Shiong expressed frustration with the slow pace of reimbursement and urged investor patience.

Quest also announced a partnership to provide supply chain expertise and run lab reference testing for Regional Medical Center Health System.

With the new five-year funding, patients across Australia with rare or less common cancers will be able to access the program through a network of eight cancer centers.

Under the terms of the settlement, the lawsuit, counterclaims, and challenges to the patent in inter partes review have been dismissed.

Three vendors applied their variant calling and interpretation pipelines to the same tumor NGS panel data and came up with overlapping but different results.